Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.
The company reported total revenue of $4.20 billion, falling short of analysts’ expectations of $4.29 billion, according to Benzinga Pro. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms.
The revenue shortfall was primarily driven by weaker sales in Teva’s generic drug portfolio. Specifically, the decline in generic revenues from its International Markets segment, compounded by the divestment of its Japanese business and a drop in sales from Copaxone, weighed on overall results.
Also Read: Generic Revlimid Fades, But Teva’s Broader Generics Outlook Remains Strong
However, these declines were partially offset by strong sales growth from Teva’s innovative drug offerings, including Austedo, Uzedy, and Ajovy.
Sales of Copaxone, a key multiple sclerosis treatment, fell by 23%, contributing just $62 million in revenue for the quarter. On a more positive note, Teva’s innovative portfolio saw impressive growth.
Austedo, an FDA-approved treatment for tardive dyskinesia, saw a 19% increase in sales, reaching $498 million. Uzedy, used in the treatment of schizophrenia, more than doubled its sales, totaling $54 million. Similarly, Ajovy, a migraine treatment, reported a 31% year-over-year increase, bringing in $155 million.
Teva’s generic segment showed stable performance overall. Global generics revenues declined by 2% in …